Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 12.31%, which has investors questioning if this is right time to sell.

Vtama and Zoryve have different mechanisms of action, but are lumped together into the newer novel agents class that are indicated for all levels of severity in psoriasis. Unlike traditional ...

Approval in atopic dermatitis could unlock additional sales momentum for Zoryve, which is available in a 0.3% cream for psoriasis and a 0.3% topical foam for seborrheic dermatitis. Those ...

(RTTNews) - Arcutis Canada announced that Health Canada has approved ZORYVE for the treatment of mild to moderate atopic dermatitis in adults and children ages 6 years and older. The approval of ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

Whether you’re just starting psoriasis treatment or are looking for more effective therapies for your symptoms, it helps to remember these important steps to take — and to avoid. If you’re ...

Psoriasis frequently appears on the arms, often on your elbow. Several types of psoriasis may affect your arms, but plaque psoriasis is the most common. The earliest sign may be a small bump, but the ...

After hours: March 20 at 7:53:41 PM EDT Loading Chart for ARQT ...

The FDA unveiled the Chemical Contaminants Transparency Tool, a searchable online database that provides a list of chemical contaminant types and levels used to evaluate possible harm in foods ...